Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough gout: drug combo targets uric acid after other treatments fail

NCT ID NCT07116746

Disease control Sponsor: Arthrosi Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called AR882, taken with a standard gout medication (XOI), in 15 people with severe, uncontrolled gout who have already failed uricase therapy. The goal is to see if the combination can lower uric acid levels and shrink painful uric acid crystal deposits called tophi. Researchers will also monitor for side effects over 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AR882 (a drug that lowers uric acid) combined with a xanthine oxidase inhibitor (XOI)
What this could lead to
If it works, this could offer a new treatment option for people with severe gout who have not responded to or cannot tolerate uricase therapy.
What could go wrong
This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to control gout long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of uncontrolled gout * Presence of ≥1 clinically visible tophus * Last uricase infusion occurred ≥3 months * Body weight no less than 50 kg * Serum creatinine must be \< 3.0 mg/dL and estimated CLcr ≥ 40 mL/min Exclusion Criteria: * Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin * Pregnant or breastfeeding * History of symptomatic kidney stones within the past 6 months * Received pegloticase, rasburicase or other experimental uricases within the last 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gout are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arthritis, Gouty gout Hyperuricemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gout Gout chronic Gouty arthritis Hyperuricemia Refractory gout Tophaceous gout Uncontrolled gout

Contacts and locations

Locations

  • Arthrosi Investigative Site (102)

    Miami, Florida, 33155, United States

  • Arthrosi Investigative Site (103)

    Duncansville, Pennsylvania, 16635, United States

  • Arthrosi Investigative Site (104)

    West Lake Hills, Texas, 78746, United States

  • Arthrosi Investigative Site (105)

    Margate, Florida, 33063, United States

  • Arthrosi Investigative Site (106)

    Jackson, Mississippi, 39202, United States

  • Arthrosi Investigative Site (107)

    Bellevue, Washington, 98004, United States

  • Arthrosi Investigative Site (108)

    Charlotte, North Carolina, 28202, United States

  • Arthrosi Investigative Site (109)

    Tampa, Florida, 33609, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.